144 related articles for article (PubMed ID: 1287915)
1. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom.
Scott JA; Davidson RN; Moody AH; Grant HR; Felmingham D; Scott GM; Olliaro P; Bryceson AD
Trans R Soc Trop Med Hyg; 1992; 86(6):617-9. PubMed ID: 1287915
[TBL] [Abstract][Full Text] [Related]
2. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis.
Soto J; Grogl M; Berman J; Olliaro P
Trans R Soc Trop Med Hyg; 1994; 88(6):695-8. PubMed ID: 7886777
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.
Asilian A; Jalayer T; Nilforooshzadeh M; Ghassemi RL; Peto R; Wayling S; Olliaro P; Modabber F
Bull World Health Organ; 2003; 81(5):353-9. PubMed ID: 12856053
[TBL] [Abstract][Full Text] [Related]
4. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.
Chunge CN; Owate J; Pamba HO; Donno L
Trans R Soc Trop Med Hyg; 1990; 84(2):221-5. PubMed ID: 2167522
[TBL] [Abstract][Full Text] [Related]
5. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.
Hepburn NC; Tidman MJ; Hunter JA
Trans R Soc Trop Med Hyg; 1994; 88(6):700-3. PubMed ID: 7886779
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran.
Asilian A; Jalayer T; Whitworth JA; Ghasemi RL; Nilforooshzadeh M; Olliaro P
Am J Trop Med Hyg; 1995 Dec; 53(6):648-51. PubMed ID: 8561269
[TBL] [Abstract][Full Text] [Related]
7. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
Jha TK; Olliaro P; Thakur CP; Kanyok TP; Singhania BL; Singh IJ; Singh NK; Akhoury S; Jha S
BMJ; 1998 Apr; 316(7139):1200-5. PubMed ID: 9583927
[TBL] [Abstract][Full Text] [Related]
8. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
9. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
[TBL] [Abstract][Full Text] [Related]
10. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
11. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
12. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis.
Neal RA; Murphy AG; Olliaro P; Croft SL
Trans R Soc Trop Med Hyg; 1994; 88(2):223-5. PubMed ID: 8036682
[TBL] [Abstract][Full Text] [Related]
13. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica.
Teklemariam S; Hiwot AG; Frommel D; Miko TL; Ganlov G; Bryceson A
Trans R Soc Trop Med Hyg; 1994; 88(3):334-9. PubMed ID: 7974682
[TBL] [Abstract][Full Text] [Related]
14. Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).
Vexenat JA; Olliaro PL; Fonseca de Castro JA; Cavalcante R; Furtado Campos JH; Tavares JP; Miles MA
Am J Trop Med Hyg; 1998 Apr; 58(4):448-53. PubMed ID: 9574790
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
16. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London.
Bryceson AD; Murphy A; Moody AH
Trans R Soc Trop Med Hyg; 1994; 88(2):226-8. PubMed ID: 8036683
[TBL] [Abstract][Full Text] [Related]
18. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
19. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
[TBL] [Abstract][Full Text] [Related]
20. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.
Seaman J; Pryce D; Sondorp HE; Moody A; Bryceson AD; Davidson RN
J Infect Dis; 1993 Sep; 168(3):715-20. PubMed ID: 8394861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
